The market dynamics for Schizophrenia are witnessing substantial growth driven by the increasing prevalence of schizophrenia, rising awareness regarding mental health disorders, advancements in psychiatric research, growing adoption of long-acting injectable therapies, and the development of novel antipsychotic agents with improved efficacy and safety profiles. Additionally, the launch of emerging therapies such as olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Schizophrenia Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Schizophrenia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Schizophrenia Market

• The market size for Schizophrenia in the leading markets is expected to grow significantly by 2036.

• The schizophrenia market size in the 7MM was more than USD 8 billion in 2025 and is further expected to increase by 2036.

• Among the 7MM, the United States accounted for the largest schizophrenia market size in 2025 with nearly USD 6 billion, compared to EU4 countries, the United Kingdom, and Japan.

• DelveInsight’s analysis suggests that in 2025 the total diagnosed prevalent cases of schizophrenia in the 7MM were nearly 4 million cases, of which the US accounted for approximately 1.5 million cases.

• Among EU4 and the UK, nearly 42% of the total diagnosed prevalent schizophrenia cases were reported in 2025.

• According to DelveInsight’s analysis, males are more susceptible to schizophrenia due to genetic, hormonal, and neurodevelopmental factors. In 2025, the diagnosed prevalence in the US was approximately 780,000 for males and 670,000 for females.

• In 2025, Germany accounted for nearly 450,000 diagnosed prevalent cases of schizophrenia, representing the highest burden among EU4 countries and the UK.

• In 2025, Japan accounted for approximately 1 million prevalent cases of schizophrenia, of which nearly 790,000 were diagnosed.

• According to WHO, nearly 50% of mental hospital patients globally have schizophrenia, but only 31.3% of those with psychosis receive specialized care.

• Leading schizophrenia companies, such as Teva Pharmaceutical Industries, Otsuka Pharmaceuticals, Sumitomo Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Newron Pharmaceuticals, Bristol Myers Squibb, and others, are developing novel schizophrenia therapies to improve treatment outcomes and address unmet needs.

• The promising schizophrenia therapies in development include olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Schizophrenia Market

• Rising Disease Prevalence and Awareness:- Increasing awareness regarding schizophrenia, improvements in psychiatric diagnosis, and reduction in social stigma associated with mental health disorders are contributing to greater diagnosis and treatment rates globally.

• Increasing Adoption of Long-Acting Injectable Therapies: – Long-acting injectable (LAI) therapies are gaining traction due to improved patient adherence, reduced relapse rates, and enhanced long-term symptom control compared to oral therapies.

• Growing Demand for Novel Mechanism-Based Therapies: – Current antipsychotics primarily target dopamine pathways but are often associated with metabolic side effects and limited efficacy against negative and cognitive symptoms. Emerging therapies targeting TAAR1, glycine transporters, serotonin receptors, and glutamate pathways are expected to transform the schizophrenia treatment landscape.

• Advancements in Personalized and Holistic Care Approaches: – Psychosocial interventions, cognitive behavioral therapy, supported employment programs, digital psychiatry solutions, and patient-centered care models are increasingly being integrated into schizophrenia management.

Schizophrenia Competitive Landscape

• Several schizophrenia drugs in development include olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), and others.

• These candidates target diverse mechanisms such as TAAR1 agonism, serotonin-dopamine modulation, sigma receptor antagonism, glutamatergic modulation, and long-acting injectable delivery systems to improve efficacy, adherence, and management of both positive and negative symptoms of schizophrenia.

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

Recent Developments in the Schizophrenia Market

• In September 2024, the US FDA approved Bristol Myers Squibb’s COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adults, representing the first novel schizophrenia mechanism in decades without D2 receptor blockade.

• In February 2026, the US FDA accepted Teva Pharmaceutical Industries’ NDA for olanzapine extended-release injectable suspension (TEV-’749), intended for once-monthly schizophrenia treatment in adults.

• In January 2026, Reviva Pharmaceuticals announced publication of clinical vocal biomarker data from the RECOVER Phase III trial evaluating brilaroxazine in schizophrenia patients.

• In October 2025, Minerva Neurosciences secured financing of up to USD 200 million to support the Phase III confirmatory trial and regulatory advancement of roluperidone for schizophrenia negative symptoms.

• In July 2023, Sumitomo Pharma and Otsuka reported Phase III DIAMOND trial results for ulotaront (SEP-363856), while Otsuka continued Phase III development activities in the US.

What is Schizophrenia?

Schizophrenia is a severe chronic mental disorder that affects thinking, emotions, perception, decision-making, and social functioning. The disease commonly manifests during late adolescence or early adulthood and is characterized by psychotic symptoms including hallucinations, delusions, disorganized thinking, negative symptoms, and cognitive impairments.

The diagnosis of schizophrenia involves psychiatric evaluation, clinical interviews, exclusion of other psychiatric or neurological disorders, and assessment tools such as PANSS, CGI, and SANS scales to evaluate symptom severity. Treatment generally involves pharmacotherapy, psychosocial interventions, counseling, behavioral therapy, and social support programs aimed at improving long-term patient functioning and quality of life.

Schizophrenia Epidemiology Segmentation

The Schizophrenia epidemiology section provides insights into the historical and current schizophrenia patient pool and forecasted trends for the leading markets. The schizophrenia market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

• Total Prevalent Cases of Schizophrenia

• Total Diagnosed Prevalent Cases of Schizophrenia

• Gender-specific Diagnosed Prevalent Cases of Schizophrenia

• Severity-specific Diagnosed Prevalent Cases of Schizophrenia

• Age-specific Diagnosed Prevalent Cases of Schizophrenia

Scope of the Schizophrenia Market Report

• Therapeutic Assessment: Schizophrenia current marketed and emerging therapies

• Schizophrenia Market Dynamics: Key Market Forecast Assumptions and Market Outlook

• Key Companies: Teva Pharmaceutical Industries, Otsuka Pharmaceuticals, Sumitomo Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Newron Pharmaceuticals, Bristol Myers Squibb, and others

• Key Therapies: COBENFY, olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), REXULTI, CAPLYTA, VRAYLAR, LATUDA, INVEGA products, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Schizophrenia Market Report Introduction

2. Executive Summary for Schizophrenia

3. SWOT Analysis of Schizophrenia

4. Schizophrenia Patient Share (%) Overview at a Glance

5. Schizophrenia Market Overview at a Glance

6. Schizophrenia Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Schizophrenia

9. Schizophrenia Current Treatment and Medical Practices

10. Schizophrenia Unmet Needs

11. Schizophrenia Emerging Therapies

12. Schizophrenia Market Outlook

13. Country-Wise Schizophrenia Market Analysis (2022–2036)

14. Schizophrenia Market Access and Reimbursement of Therapies

15. Schizophrenia Market Drivers

16. Schizophrenia Market Barriers

17. Schizophrenia Appendix

18. Schizophrenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services